Skip to main content
. 2014 Apr 21;9(4):e95762. doi: 10.1371/journal.pone.0095762

Figure 1. Infarct area when C21 is given as a pre-treatment.

Figure 1

Histological sections showing typical infarcted (darker area) and non-infarcted regions from SHR that were either treated with (A) vehicle, (B) AT2R agonist C21 50 ng/kg/min or (C) C21 50 ng/kg/min+PD123319 36 ng/kg/min. Mean data±SEM for infarct volume taken 72 hours post stroke in (D) cortical and (E) striatal regions on the ipsilateral side are shown for vehicle (n = 11), C21 at 5 ng/kg/min (n = 8), 10 ng/kg/min (n = 11) and 50 ng/kg/min (n = 11), AT2R antagonist PD123319 alone (n = 10) and in combination with C21 50 ng/kg/min (n = 11). *P<0.05 vs. vehicle (1-way ANOVA).